08:43 AM EDT, 06/27/2025 (MT Newswires) -- Autonomix Medical ( AMIX ) said Friday it received a new US patent covering its catheter-based nerve-targeting technology used to identify and treat neurological signals.

The company said the patent includes methods for detecting and modifying nerve activity during procedures such as denervation or neuromodulation, and the tools to reach small vessels near tumors.

Autonomix said it plans to file for investigational device exemption with the US Food and Drug Administration and begin US trials this year that will back a labeling indication to commercialize the Autonomix sensing and RF ablation system in the US as a treatment for pancreatic cancer pain.

Shares of the company were 4% higher in recent premarket activity.